CLINICAL DYNAMICS

Study Name: Human PIK3CA Gene Mutation Detection Kit (Fluorescent PCR Method) Clinical Trial
Site: Cancer Hospital Chinese Academy of Medical Sciences
Sponsor: QIAGEN Shanghai
Third-party Lab: RuiBiotech Beijing
HGRAC Approval Time: October 2023
Note: HGRAC Approval or Filing (Human Genetic Resource Administration of China) is an important step before the first enrollment of subjects for clinical trials in China sponsored by foreign companies.

Study Name: Exploratory Clinical Study on the Safety and Efficacy of Vascular Intervention Surgery Control System Combined with Thrombectomy Stent and Microcatheter in Treating Acute Ischemic Stroke
Site: Beijing Tiantan Hospital, Capital Medical University
Sponsor: Hangzhou Dinova Brain Nerve MedTech
HGRAC Approval Time: October 2023
Note: HGRAC Approval or Filing (Human Genetic Resource Administration of China) is an important step before the first enrollment of subjects for clinical trials in China sponsored by foreign companies.

Study Name: A Real-World Study Evaluating the Clinical Performance and Safety of the Da Vinci SP Single-Port Endoscopic Surgery System for Thoracoscopic Single-Port Surgery
Site: Hainan Hospital of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (Hainan Boao Research Hospital)
Sponsor: Intuitive Surgical, Inc.
HGRAC Approval Time: October 2023
Note: HGRAC Approval or Filing (Human Genetic Resource Administration of China) is an important step before the first enrollment of subjects for clinical trials in China sponsored by foreign companies.

Study name: A Single-Center, Single-Arm, Prospective Real-World Study to Evaluate the Safety and Efficacy of the pEGASUS Intracranial Stent in Assisting the Treatment of Intracranial Aneurysms
Leading site: Hainan Hospital of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (Hainan Boao Research Hospital)
Sponsor: Wallaby Medical
HGRAC Approval Time: October 2023
Note: HGRAC Approval or Filing (Human Genetic Resource Administration of China) is an important step before the first enrollment of subjects for clinical trials in China sponsored by foreign companies.